I tend to agree with Russ ahz has had a very good run but i seriously think this is still at the very beginning.They have income Cardiocel will be huge and that technology will be used for pelvic floor reconstruction and hernia repairs which when you delve into it is a huge market. The potential returns from this bios technology are very large then as a sidelight you have a potential vaccine for herpes simplex 2.Just consider if this is successful the returns.This co bio bubble or not could very easily be the next great success story in aussie biotech land imo
